Abstract
Extracorporeal photopheresis (ECP) was given to 23 patients with steroid-refractory acute GVHD (aGVHD, grade II (n=10), III (n=7) or IV (n=6)). The median duration of ECP was 7 months (1-33) and the median number of ECP cycles in each patient was 10. Twelve patients (52%) had complete responses. Eleven patients (48%) survived and 12 died, 10 of GVHD with or without infections and two of leukaemia relapse. The average grade of GVHD was reduced from 2.8 (on the first day of ECP) to 1.4 (on day +90 from ECP) (P=0.08), and the average dose of i.v. methylprednisolone from 2.17 to 0.2mg/kg/d (P=0.004). Complete responses were obtained in 70, 42 and 0% of patients, respectively, with grades II, III and IV aGVHD; complete responses in the skin, liver and gut were 66, 27 and 40%. Patients treated within 35 days from onset of aGVHD had higher responses (83 vs 47%; P=0.1). A trend for improved survival was seen in grade III-IV aGVHD treated with ECP as compared to matched controls (38 vs 16%; P 0.08). ECP is a treatment option for patients with steroid refractory aGVHD and should be considered early in the course of the disease.
| Original language | English |
|---|---|
| Pages (from-to) | 609-617 |
| Number of pages | 9 |
| Journal | Bone Marrow Transplantation |
| Volume | 42 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2008 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. / Perfetti, P.; Carlier, P.; Strada, P.; Gualandi, F.; Occhini, D.; Van Lint, M. T.; Ibatici, A.; Lamparelli, T.; Bruno, B.; Raiola, A. M.; Dominietto, A.; Di Grazia, C.; Bregante, S.; Zia, S.; Ferrari, G. M.; Stura, P.; Pogliani, E.; Bacigalupo, A.
In: Bone Marrow Transplantation, Vol. 42, No. 9, 2008, p. 609-617.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD
AU - Perfetti, P.
AU - Carlier, P.
AU - Strada, P.
AU - Gualandi, F.
AU - Occhini, D.
AU - Van Lint, M. T.
AU - Ibatici, A.
AU - Lamparelli, T.
AU - Bruno, B.
AU - Raiola, A. M.
AU - Dominietto, A.
AU - Di Grazia, C.
AU - Bregante, S.
AU - Zia, S.
AU - Ferrari, G. M.
AU - Stura, P.
AU - Pogliani, E.
AU - Bacigalupo, A.
PY - 2008
Y1 - 2008
N2 - Extracorporeal photopheresis (ECP) was given to 23 patients with steroid-refractory acute GVHD (aGVHD, grade II (n=10), III (n=7) or IV (n=6)). The median duration of ECP was 7 months (1-33) and the median number of ECP cycles in each patient was 10. Twelve patients (52%) had complete responses. Eleven patients (48%) survived and 12 died, 10 of GVHD with or without infections and two of leukaemia relapse. The average grade of GVHD was reduced from 2.8 (on the first day of ECP) to 1.4 (on day +90 from ECP) (P=0.08), and the average dose of i.v. methylprednisolone from 2.17 to 0.2mg/kg/d (P=0.004). Complete responses were obtained in 70, 42 and 0% of patients, respectively, with grades II, III and IV aGVHD; complete responses in the skin, liver and gut were 66, 27 and 40%. Patients treated within 35 days from onset of aGVHD had higher responses (83 vs 47%; P=0.1). A trend for improved survival was seen in grade III-IV aGVHD treated with ECP as compared to matched controls (38 vs 16%; P 0.08). ECP is a treatment option for patients with steroid refractory aGVHD and should be considered early in the course of the disease.
AB - Extracorporeal photopheresis (ECP) was given to 23 patients with steroid-refractory acute GVHD (aGVHD, grade II (n=10), III (n=7) or IV (n=6)). The median duration of ECP was 7 months (1-33) and the median number of ECP cycles in each patient was 10. Twelve patients (52%) had complete responses. Eleven patients (48%) survived and 12 died, 10 of GVHD with or without infections and two of leukaemia relapse. The average grade of GVHD was reduced from 2.8 (on the first day of ECP) to 1.4 (on day +90 from ECP) (P=0.08), and the average dose of i.v. methylprednisolone from 2.17 to 0.2mg/kg/d (P=0.004). Complete responses were obtained in 70, 42 and 0% of patients, respectively, with grades II, III and IV aGVHD; complete responses in the skin, liver and gut were 66, 27 and 40%. Patients treated within 35 days from onset of aGVHD had higher responses (83 vs 47%; P=0.1). A trend for improved survival was seen in grade III-IV aGVHD treated with ECP as compared to matched controls (38 vs 16%; P 0.08). ECP is a treatment option for patients with steroid refractory aGVHD and should be considered early in the course of the disease.
UR - http://www.scopus.com/inward/record.url?scp=56349140988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56349140988&partnerID=8YFLogxK
U2 - 10.1038/bmt.2008.221
DO - 10.1038/bmt.2008.221
M3 - Article
C2 - 18660840
AN - SCOPUS:56349140988
VL - 42
SP - 609
EP - 617
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 9
ER -